Krystal Biotech maintains a multi-billion-dollar market capitalization, reflecting investor confidence in its commercial execution, revenue growth, and scalable pipeline potential. The market capitalization fluctuates dynamically during active trading sessions as the share price responds to quarterly earnings reports, clinical trial updates, and broader market movements. This valuation places the firm securely among prominent commercial-stage biotechnology enterprises. Detailed and real-time market cap tracking is available through standard financial market terminals, stock exchanges, and investment tracking platforms, reflecting the aggregate market value assigned to the company's total outstanding common shares.